She Medicine (畲药) Diren Zishen Formula (地稔滋肾方) Combined with Acupuncture as Adjunctive Treatment for 32 Cases of Primary Biliary Cholangitis with Liver and Kidney Yin Deficiency Syndrome
|更新时间:2024-01-11
|
She Medicine (畲药) Diren Zishen Formula (地稔滋肾方) Combined with Acupuncture as Adjunctive Treatment for 32 Cases of Primary Biliary Cholangitis with Liver and Kidney Yin Deficiency Syndrome
Journal of Traditional Chinese MedicineVol. 65, Issue 2, Pages: 198-204(2024)
LI Shiguo,PAN quan,JIANG Liping,et al.She Medicine (畲药) Diren Zishen Formula (地稔滋肾方) Combined with Acupuncture as Adjunctive Treatment for 32 Cases of Primary Biliary Cholangitis with Liver and Kidney Yin Deficiency Syndrome[J].Journal of Traditional Chinese Medicine,2024,65(02):198-204.
LI Shiguo,PAN quan,JIANG Liping,et al.She Medicine (畲药) Diren Zishen Formula (地稔滋肾方) Combined with Acupuncture as Adjunctive Treatment for 32 Cases of Primary Biliary Cholangitis with Liver and Kidney Yin Deficiency Syndrome[J].Journal of Traditional Chinese Medicine,2024,65(02):198-204.DOI: 10.13288/j.11-2166/r.2024.02.014.
She Medicine (畲药) Diren Zishen Formula (地稔滋肾方) Combined with Acupuncture as Adjunctive Treatment for 32 Cases of Primary Biliary Cholangitis with Liver and Kidney Yin Deficiency Syndrome
To observe the clinical effectiveness and safety of
She medicine
(畲药)
Diren Zishen Formula
(地稔滋肾方) combined with acupuncture as adjunctive treatment for primary biliary cholangitis with liver and kidney
yin
deficiency syndrome.
Methods
2
Seventy patients of primary biliary cholangitis with liver and kidney
yin
deficiency syndrome were randomly divided into a control group and a treatment group, with 35 patients in each group. The control group received oral ursodeoxycholic acid capsules (250 mg per dose, three times daily). The treatment group received
She medicine
Diren Zishen Formula
oral decoction (one dose daily, 200 ml per dose in the morning and evening, served warm) and acupuncture [bilateral Sanyingjiao (SP6), Taichong (LR3), Ganshu (BL18), Zusanli (ST36), Fenglong (ST17), once daily, 5 consecutive days per week] in addition to the same treatment as the control group. The treatment duration was three months for both groups. Comparisons were made between the two groups before and after treatment for the following parameters, which were four traditional Chinese medicine (TCM) symptoms scores (skin itching, fatigue, jaundice, and flank pain), TCM syndrome scores, liver function indicators including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and total bilirubin (TBiL), liver fibrosis markers including serum laminin (LN), serum hyaluronic acid (HA), serum type Ⅳ collagen (Ⅳ-C) and serum type Ⅲ procollagen (PC-Ⅲ), and inflammatory factor indicators including serum interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). The effectiveness of TCM syndrome between the two groups was compared and safety evaluations were also conducted after treatment.
Results
2
A total of 32 cases were finally analyzed in the treatment group, while the control group had 31 cases. The total effective rate of TCM syndrome in the treatment group (87.50%, 28/32) was higher than that in the control group (67.74%, 20/31) (
P
<0.05). After treatment, the TCM symptom scores, syndrome scores, liver function, and liver fibrosis markers in both groups signi-ficantly decreased, while in the treatment group, the inflammatory factor indicators decreased after treatment, and more decreases were found than those in the control group (
P
<0.05 or
P
<0.01). Both groups had good safety, and no adverse reactions were observed.
Conclusion
2
The combination of
She medicine
Diren Zishen Formula
and acupuncture as an adjunctive treatment for primary biliary cholangitis can significantly improve the clinical effectiveness, improve liver function, reduce inflammatory response, and alleviate liver fibrosis, with good safety.
MURILLO PEREZ CF , HARMS MH , LINDOR KD , et al . Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase [J]. Am J Gastroenterol , 2020 , 115 ( 7 ): 1066 - 1074 .